MYF-5 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-93518
Key Product Details
Species Reactivity
Human
Applications
Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence PECNSPVWSRKSST corresponding to internal region according to NP_005584.1.
Epitope
PECNSPVWSRKSST
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for MYF-5 Antibody
Western Blot: MYF-5 Antibody [NB100-93518]
Western Blot: MYF-5 Antibody [NB100-93518] - (0.5ug/ml) staining of Muscle lysate (35ug protein in RIPA buffer) with (B) and without (A) blocking with the immunising peptide. Primary incubation was 1 hour. Detected by chemiluminescence.Applications for MYF-5 Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:32000
Western Blot
0.5 - 1.5 ug/ml
Application Notes
WB: Approx. 28 kDa band observed in human skeletal muscle lysates (calculated MW of 28.4 kDa band according to NP_005584.1).
An additional band of 26 kDa band was consistently observed, however this band was not blocked by the immunizing peptide and it is therefore a non-specific signal. We call for caution when used for other assays than WB.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: MYF-5
Long Name
Myogenic Regulatory Factor 5
Alternate Names
bHLHc2, MYF5
Entrez Gene IDs
4617 (Human)
Gene Symbol
MYF5
UniProt
Additional MYF-5 Products
Product Documents for MYF-5 Antibody
Product Specific Notices for MYF-5 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...